vimarsana.com
Home
Live Updates
Monte Rosa Therapeutics Presents Preclinical Data at Digesti
Monte Rosa Therapeutics Presents Preclinical Data at Digesti
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
MRT-6160, a VAV1-directed molecular glue degrader , inhibits colitis disease progression and colon inflammation, lowers inflammatory mucosal cytokines, and reduces expression of IBD-associated genes...
Related Keywords
Washington ,
United States ,
Boston ,
Massachusetts ,
Cory Tromblee ,
Monte Rosa ,
Andrew Funderburk ,
Markus Warmuth ,
Monte Rosa Qu ,
Marisa Peluso ,
Nasdaq ,
Exchange Commission ,
Company Qu ,
Company Mgds ,
Globenewswire Inc ,
Monte Rosa Therapeutics Inc ,
Rosa Therapeutics ,
Digestive Disease Week ,
T Andb Cell ,
Chief Executive Officer ,
Directed Molecular Glue Degrader ,
Inhibits Disease Progression ,
Reduced Calprotectin ,
Ddiscovery Biology ,
Pre Clinical Treatment ,
Intestinal Inflammation ,
Engineered Elimination ,
Private Securities Litigation Reform Act ,
Annual Report ,